Apollomics (NASDAQ:APLM) Shares Down 1.3% – Time to Sell?

Shares of Apollomics Inc. (NASDAQ:APLM) were down 1.3% during trading on Monday . The company traded as low as $18.43 and last traded at $19.00. Approximately 2,894 shares were traded during mid-day trading, a decline of 79% from the average daily volume of 13,538 shares. The stock had previously closed at $19.25.

Wall Street Analyst Weigh In

APLM has been the topic of several research reports. Wall Street Zen raised shares of Apollomics from a “sell” rating to a “hold” rating in a report on Saturday, January 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Apollomics in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has an average rating of “Sell”.

Apollomics Stock Performance

The company’s 50 day moving average is $18.66 and its 200-day moving average is $15.32.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.